Peiminine ameliorates bleomycin-induced acute lung injury in rats

Molecular Medicine Reports

Volumn 7, Issue 4, 2013, Pages 1103-1110

  Guo, Hai ^a   Ji, Fuzhi ^a   Liu, Baorui ^a,b   Chen, Xiaofei ^a   He, Jingdong ^a   Zhao, Xiaofeng ^a   Gong, Jiening ^c  

^a THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cellular signal transduction pathways; Inflammatory cytokines; Peiminine; Pulmonary fibrosis

Indexed keywords

BLEOMYCIN; CARBOXYMETHYLCELLULOSE; CHINESE DRUG; CONNECTIVE TISSUE GROWTH FACTOR; DEXAMETHASONE; EOSIN; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; HEMATOXYLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEIMININE; PLANT MEDICINAL PRODUCT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG INHIBITION; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG INDEX; LUNG PARENCHYMA; LUNG WEIGHT; NONHUMAN; PULMONARY INTERSTITIAL INFLAMMATION; RADIOIMMUNOASSAY; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION;

ACUTE LUNG INJURY; ANIMALS; BLEOMYCIN; CEVANES; COLLAGEN TYPE I; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; PNEUMONIA; PULMONARY FIBROSIS; RATS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875235131     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1312     Document Type: Article

References (38)

1. Limper AH: Chemotherapy-induced lung disease. Clin Chest Med 25: 53-64, 2004.
2. Graves PR, Siddiqui F, Anscher MS and Movsas B: Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol 20: 201-207, 2010.
3. Bhatia M, Zemans RL and Jeyaseelan S: Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol 46: 566-572, 2012.
4. Martin TR and Matute-Bello G: Experimental models and emerging hypotheses for acute lung injury. Crit Care Clin 27: 735-752, 2011.
5. Mukhopadhyay S, Hoidal JR and Mukherjee TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res 7: 125, 2006.
6. Anscher MS: Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 15: 350-359, 2010.
7. Wilson MS, Madala SK, Ramalingam TR, et al: Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207: 535-552, 2010.
8. Blom IE, Goldschmeding R and Leask A: Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21: 473-482, 2002.
9. Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S and Hardie WD: MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am J Respir Cell Mol Biol 46: 380-388, 2012.
10. Antoniou KM, Margaritopoulos GA, Soufla G, et al: Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recept Signal Transduct Res 30: 262-269, 2010.
11. Jia X, Liu B, Shi X, Ye M, Zhang F and Liu H: Roles of the ERK, JNK/AP-1/cyclin D1-CDK4 pathway in silica-induced cell cycle changes in human embryo lung fibroblast cells. Cell Biol Int 35: 697-704, 2011.
12. Morris GF: An alternative to lung inflammation and fibrosis. Am J Pathol 176: 2595-2598, 2010.
13. Vallabhapurapu S and Karin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733, 2009.
14. Johnson ER and Matthay MA: Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 23: 243-252, 2010.
15. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N and Meade M: Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care 25: 420-435, 2010.
16. Raghu G, Collard HR, Egan JJ, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
17. Wang D, Zhu J, Wang S, et al: Antitussive, expectorant and anti-inflammatory alkaloids from Bulbus Fritillariae Cirrhosae. Fitoterapia 82: 1290-1294, 2011.
18. Wang D, Wang S, Chen X, et al: Antitussive, expectorant and anti-inflammatory activities of four alkaloids isolated from Bulbus of Fritillaria wabuensis. J Ethnopharmacol 139: 189-193, 2012.
19. Taooka Y, Maeda A, Hiyama K, Ishioka S and Yamakido M: Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 156: 260-265, 1997.
20. Aono Y, Nishioka Y, Inayama M, et al: Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171: 1279-1285, 2005.
21. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW and Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 120: 893-899, 1979.
22. El-Demerdash E: Anti-inflammatory and antifibrotic effects of methyl palmitate. Toxicol Appl Pharmacol 254: 238-244, 2011.
23. Kim JW, Rhee CK, Kim TJ, et al: Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis. Clin Exp Pharmacol Physiol 37: 1055-1063, 2010.
24. Hardie WD, Glasser SW and Hagood JS: Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 175: 3-16, 2009.
25. Zhao L, Wang X, Chang Q, et al: Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmacol 627: 304-312, 2010.
26. Liu Y, Wu H, Nie YC, Chen JL, Su WW and Li PB: Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway. Int Immunopharmacol 11: 1606-1612, 2011.
27. Lee HB, Kim EK, Park SJ, Bang SG, Kim TG and Chung DW: Isolation and anti-inflammatory effect of astragalin synthesized by enzymatic hydrolysis of tea seed extract. J Sci Food Agric 91: 2315-2321, 2011.
28. Fu PK, Wu CL, Tsai TH and Hsieh CL: Anti-inflammatory and anticoagulative effects of paeonol on LPS-induced acute lung injury in rats. Evid Based Complement Alternat Med 2012: 837513, 2012.
29. Lee JP, Li YC, Chen HY, et al: Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils. Acta Pharmacol Sin 31: 831-838, 2010.
30. Soromou LW, Chen N, Jiang L, et al: Astragalin attenuates lipopolysaccharide-induced inflammatory responses by down-regulating NF-κB signaling pathway. Biochem Biophys Res Commun 419: 256-261, 2012.
31. Levings MK and Schrader JW: IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol 162: 5224-5229, 1999.
32. Carey WA, Taylor GD, Dean WB and Bristow JD: Tenascin-C deficiency attenuates TGF-β-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol 299: L785-L793, 2010.
33. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.
34. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
35. Ramos C, Becerril C, Montano M, et al: FGF-1 reverts epithelial- mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol 299: L222-L231, 2010.
36. Kono M, Nakamura Y, Suda T, et al: Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta 412: 2211-2215, 2011.
37. Leask A, Parapuram SK, Shi-Wen X and Abraham DJ: Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 3: 89-94, 2009.
38. Dosreis GA, Borges VM and Zin WA: The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 8: 285-293, 2004.